Prognostic markers in rectal carcinoma.

TitlePrognostic markers in rectal carcinoma.
Publication TypeJournal Article
Year of Publication1998
AuthorsJessup JM, Loda M
JournalSemin Surg Oncol
Date Published1998 Sep
KeywordsAdenocarcinoma, Biomarkers, Tumor, Carcinoembryonic Antigen, Cell Transformation, Neoplastic, Gene Expression Regulation, Neoplastic, Genes, DCC, Genes, p53, Humans, Ploidies, Prognosis, Rectal Neoplasms

Guidelines from two major organizations have recently supported the use of only the serological marker carcinoembryonic antigen (CEA) for the prognostication and monitoring of patients with colorectal carcinoma. However, in view of the exciting advances made recently in elucidating the molecular and cellular biology of adenocarcinoma of the rectum, the molecules that transform the well-ordered normal rectal epithelium into an invasive adenocarcinoma may yield information about the ultimate behavior of that cancer. Consequently, assessing the expression of molecules within a primary cancer may predict the probability of regional and distant metastasis, response to therapy, and outcome. This review analyzes the current state of intratumoral expression of several molecular markers for the management of rectal cancer and evaluates their potential for defining which patients may undergo rectal sphincter preservation and need adjuvant therapy.

Alternate JournalSemin Surg Oncol
PubMed ID9730420
Grant ListCA 42857 / CA / NCI NIH HHS / United States
CA 44704 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700